We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.01%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$880M
AUM Growth
-$133M
Cap. Flow
-$37.2M
Cap. Flow %
-4.23%
Top 10 Hldgs %
31.67%
Holding
96
New
7
Increased
26
Reduced
40
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$9.09M
2
BSX icon
Boston Scientific
BSX
+$8.75M
3
TMO icon
Thermo Fisher Scientific
TMO
+$7.35M
4
HUM icon
Humana
HUM
+$7.34M
5
RPRX icon
Royalty Pharma
RPRX
+$6.15M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$16.1M
2
CNC icon
Centene
CNC
+$15.7M
3
MCK icon
McKesson
MCK
+$10.2M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.43M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
51
DELISTED
Immunogen Inc
IMGN
$5.4M 0.61%
1,200,000
-225,000
-16% -$977K
IMCR icon
52
Immunocore
IMCR
$1.73B
$5.22M 0.59%
140,000
-30,472
-18% -$990K
ALKS icon
53
Alkermes
ALKS
$8.29B
$4.47M 0.51%
150,000
-30,000
-17% -$862K
EW icon
54
Edwards Lifesciences
EW
$53B
$4.28M 0.49%
45,000
-20,000
-31% -$2.07M
ALGN icon
55
Align Technology
ALGN
$12.5B
$4.26M 0.48%
18,000
-12,000
-40% -$3.69M
AERI
56
DELISTED
Aerie Pharmaceuticals
AERI
$4.22M 0.48%
562,350
-26,850
-5% -$189K
HCA icon
57
HCA Healthcare
HCA
$89.6B
$4.2M 0.48%
+25,000
New +$5.37M
NVCR icon
58
NovoCure
NVCR
$2.02B
$4.17M 0.47%
60,000
-9,700
-14% -$731K
GKOS icon
59
Glaukos
GKOS
$10.7B
$4.09M 0.46%
89,991
-15,300
-15% -$726K
ALLO icon
60
Allogene Therapeutics
ALLO
$725M
$3.99M 0.45%
+350,000
New +$3.11M
MYOV
61
DELISTED
Myovant Sciences Ltd.
MYOV
$3.85M 0.44%
310,000
+60,700
+24% +$670K
GH icon
62
Guardant Health
GH
$22.4B
$3.83M 0.44%
95,000
– –
MGTX icon
63
MeiraGTx Holdings
MGTX
$1.21B
$3.79M 0.43%
500,000
– –
AGL icon
64
Agilon Health
AGL
$1.63B
$3.6M 0.41%
+6,600
New +$3.34M
EXAS
65
DELISTED
Exact Sciences
EXAS
$2.99M 0.34%
76,000
– –
ONEM
66
DELISTED
1Life Healthcare
ONEM
$2.94M 0.33%
375,250
– –
SGMO
67
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.9M 0.33%
700,000
-61,429
-8% -$266K
TDOC icon
68
Teladoc Health
TDOC
$1.29B
$2.82M 0.32%
85,000
-7,000
-8% -$297K
OM icon
69
Outset Medical
OM
$91.4M
$2.67M 0.3%
+12,000
New +$5.16M
VRAY
70
DELISTED
ViewRay, Inc.
VRAY
$2.65M 0.3%
1,000,000
+265,000
+36% +$798K
PGNY icon
71
Progyny
PGNY
$2.18B
$2.62M 0.3%
90,000
-10,000
-10% -$358K
HCAT icon
72
Health Catalyst
HCAT
$127M
$2.61M 0.3%
180,000
– –
NTLA icon
73
Intellia Therapeutics
NTLA
$1.68B
$2.59M 0.29%
50,000
– –
NKTX icon
74
Nkarta
NKTX
$176M
$2.46M 0.28%
+200,000
New +$2.62M
ISEE
75
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.4M 0.27%
250,000
-10,000
-4% -$126K
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Rhenman & Partners Asset Management held 96 positions worth $880M, down 13% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $37.2M in Q2 2022, closing 10 positions and reducing 40 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Royalty Pharma worth $6.31M.

  • Rhenman & Partners Asset Management's largest Q2 2022 buy was Royalty Pharma: 150,000 shares worth $6.31M.
  • Rhenman & Partners Asset Management added most to Abbott in Q2 2022, an estimated $9.09M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2022 reduction was McKesson, cutting an estimated $10.2M.
  • Rhenman & Partners Asset Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $16.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $880M portfolio in Q2 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q2 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 13% quarter-over-quarter to $880M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.